Update on Burkitt Lymphoma
Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been identified, and this has paved the way for testing novel agents in the disease. One of the challenges...
Saved in:
| Published in | Hematology/oncology clinics of North America Vol. 30; no. 6; p. 1333 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.12.2016
|
| Subjects | |
| Online Access | Get more information |
Cover
Loading…
| Abstract | Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been identified, and this has paved the way for testing novel agents in the disease. One of the challenges of most standard approaches typically used is severe treatment-related toxicity that often leads to discontinuation of therapy. To that point, there has been recent success developing intermediate intensity approaches that are well tolerated in all patient groups and maintain high cure rates in a multicenter setting. |
|---|---|
| AbstractList | Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new mutations that cooperate with MYC have been identified, and this has paved the way for testing novel agents in the disease. One of the challenges of most standard approaches typically used is severe treatment-related toxicity that often leads to discontinuation of therapy. To that point, there has been recent success developing intermediate intensity approaches that are well tolerated in all patient groups and maintain high cure rates in a multicenter setting. |
| Author | Dunleavy, Kieron Little, Richard F Wilson, Wyndham H |
| Author_xml | – sequence: 1 givenname: Kieron surname: Dunleavy fullname: Dunleavy, Kieron email: dunleavk@mail.nih.gov organization: Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: dunleavk@mail.nih.gov – sequence: 2 givenname: Richard F surname: Little fullname: Little, Richard F organization: HIV and Stem Cell Therapeutics, Cancer Therapeutic Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD 20892, USA – sequence: 3 givenname: Wyndham H surname: Wilson fullname: Wilson, Wyndham H organization: Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27888884$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1jslOw0AQRFsIRBb4ADgg_4An3ZMZz_gIEZtkKRdyjmbpURLwIts55O8JAupST3V4qhlcNm3DAHeEgpCKxUHs2iDkGQUagVhewJS0tjmVxkxgNgwHRNJo1TVMpLE_UVO433TRjZy1TfZ07D_345hVp7rbtbW7gavkvga-_es5bF6eP1ZvebV-fV89VnlQaMfcR0LlIrJUxEstU4ol6wKJ0Nm0PC_kkQtXShm0j0wmheB9RKXYSp_kHB5-vd3R1xy3Xb-vXX_a_p-U38NwPgk |
| CitedBy_id | crossref_primary_10_3324_haematol_2021_279631 crossref_primary_10_3390_cancers13205059 crossref_primary_10_1053_j_semdp_2021_04_004 crossref_primary_10_17776_csj_1344535 crossref_primary_10_1016_S2352_3026_20_30126_5 crossref_primary_10_12688_f1000research_16390_1 crossref_primary_10_17650_1818_8346_2018_13_3_76_82 crossref_primary_10_7717_peerj_16581 crossref_primary_10_1182_blood_2018_04_844472 crossref_primary_10_1186_s13027_023_00509_8 crossref_primary_10_3390_diseases9020043 crossref_primary_10_1080_08880018_2020_1759741 crossref_primary_10_3390_cancers13184527 crossref_primary_10_1016_j_toxlet_2017_06_010 crossref_primary_10_1002_ctd2_21 crossref_primary_10_2147_BLCTT_S407086 crossref_primary_10_1007_s00277_020_03974_y crossref_primary_10_3390_cancers13236021 crossref_primary_10_1177_0956462417748239 crossref_primary_10_3390_cancers13133352 crossref_primary_10_1002_ccr3_6727 crossref_primary_10_1016_j_clml_2021_03_012 crossref_primary_10_1016_j_idcr_2020_e00818 crossref_primary_10_1200_JOP_18_00148 crossref_primary_10_1200_JOP_18_00624 crossref_primary_10_1155_2020_3825312 crossref_primary_10_12677_ACM_2022_123318 crossref_primary_10_1016_j_hoc_2019_04_001 crossref_primary_10_1016_j_urology_2019_12_011 crossref_primary_10_1111_ijd_16768 crossref_primary_10_1371_journal_ppat_1012132 crossref_primary_10_1002_cam4_2975 crossref_primary_10_1016_j_biopha_2024_116970 crossref_primary_10_1038_s41420_021_00655_1 crossref_primary_10_1186_s13000_019_0876_3 crossref_primary_10_1186_s13027_021_00391_2 crossref_primary_10_3748_wjg_v27_i45_7844 crossref_primary_10_17235_reed_2022_8765_2022 crossref_primary_10_3390_life11111128 crossref_primary_10_1056_NEJMcpc1800321 crossref_primary_10_1002_ccr3_4535 crossref_primary_10_1007_s11912_020_0898_8 crossref_primary_10_1038_s41572_022_00404_3 crossref_primary_10_1016_j_biopha_2018_07_124 crossref_primary_10_5005_japi_11001_0084 crossref_primary_10_53126_MEBXXIV175 crossref_primary_10_1016_j_taap_2018_01_011 crossref_primary_10_3390_cancers14215318 |
| ContentType | Journal Article |
| Copyright | Published by Elsevier Inc. |
| Copyright_xml | – notice: Published by Elsevier Inc. |
| DBID | CGR CUY CVF ECM EIF NPM |
| DOI | 10.1016/j.hoc.2016.07.009 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1558-1977 |
| ExternalDocumentID | 27888884 |
| Genre | Journal Article Review |
| GroupedDBID | --- .1- .FO .GJ 0R~ 1P~ 34G 39C 4.4 457 4CK 53G 5GY 5RE AAEDT AAEDW AALRI AAQQT AAQXK AAWTL AAXUO ABCQX ABFRF ABJNI ABMAC ABOCM ABPPZ ABQZK ADBBV ADMUD AEFWE AEVXI AFCTW AFFNX AFRHN AFTJW AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AXIYT AZFZN B08 CGR COIAO CS3 CUY CVF DAHGL EBS ECM EIF EJD EX3 F5P FDB FEDTE FGOYB HVGLF HZ~ IH2 J5H N4W NPM O9- OC~ OO- R2- RIG SEL SES TWZ UDS UNMZH WH7 WOW Z5R ZGI ZXP |
| ID | FETCH-LOGICAL-c408t-bd104ad0e241e352ffd9e560110a8f33521b0e6a922c5bde17fccbbd044e82bf2 |
| IngestDate | Sat Sep 28 08:36:54 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | CCND3 Sporadic MYC Burkitt lymphoma ID3 TCF3 Risk-adapted Endemic |
| Language | English |
| License | Published by Elsevier Inc. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c408t-bd104ad0e241e352ffd9e560110a8f33521b0e6a922c5bde17fccbbd044e82bf2 |
| PMID | 27888884 |
| ParticipantIDs | pubmed_primary_27888884 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-12-01 |
| PublicationDateYYYYMMDD | 2016-12-01 |
| PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Hematology/oncology clinics of North America |
| PublicationTitleAlternate | Hematol Oncol Clin North Am |
| PublicationYear | 2016 |
| SSID | ssj0015084 |
| Score | 2.4009554 |
| SecondaryResourceType | review_article |
| Snippet | Because of its rarity and high curability, progress in advancing therapeutics in Burkitt lymphoma (BL) has been difficult. Over recent years, several new... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 1333 |
| SubjectTerms | Burkitt Lymphoma - genetics Burkitt Lymphoma - metabolism Burkitt Lymphoma - therapy Humans Mutation Proto-Oncogene Proteins c-myc - genetics Proto-Oncogene Proteins c-myc - metabolism |
| Title | Update on Burkitt Lymphoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27888884 |
| Volume | 30 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT4NAEN5YTYwX41vrIxy8GRqgy2OPamwabXtqY28Nu-ym1RYag4f66519IFirUS-EsIGwfDDMtzPzDUKXYSCCJiPy-6bCxh4ObRJRmTnFYIDAH09lVXZ7QXuA74f-sGzGqapLctpgbyvrSv6DKhwDXGWV7B-Q_bgoHIB9wBe2gDBsf4XxYC75ulzvv3l9eZ7k-VVnAehkxtYan7MtZVlNUUorS5lWXdIlkSqR41PspuLZTnmsGxo_wL-zDNd3JlL3uFKVX2YHl-KPj4s0GcczU_tglhXcoJKiwY0p9IFfEtNkxdhKE0OZfDF8QHWbKy2yXhx4aowzKRjpaqlUpYiQVxCazxREniTkke4Z9_Pokkh2MVRDtTCS5q4nF21MMAl8UFwEtFVq39K9SEFoc_4SuVBORn8HbRt2YF1rqHfRGk_30GbX5D_so7pG3MpSyyBuFYgfoEHrrn_btk13C5thJ8ptmgATjhOHgw_FwQ0WIiFc8mPXiSMhS-Fc6vAgJp7HfJpwNxSMUZo4GPPIo8I7ROtplvJjZGEMLN2loRMTin3GSRLG0rD6AQ1oiPEJOtKzGs21hMmomG_925FTtFW-FmdoQ8A3w8_BAcvphXq870SYLEg |
| link.rule.ids | 783 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Update+on+Burkitt+Lymphoma&rft.jtitle=Hematology%2Foncology+clinics+of+North+America&rft.au=Dunleavy%2C+Kieron&rft.au=Little%2C+Richard+F&rft.au=Wilson%2C+Wyndham+H&rft.date=2016-12-01&rft.eissn=1558-1977&rft.volume=30&rft.issue=6&rft.spage=1333&rft_id=info:doi/10.1016%2Fj.hoc.2016.07.009&rft_id=info%3Apmid%2F27888884&rft_id=info%3Apmid%2F27888884&rft.externalDocID=27888884 |